Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $20.9 million.

  • Altimmune's Operating Expenses fell 1577.59% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.5 million, marking a year-over-year decrease of 1919.88%. This contributed to the annual value of $103.2 million for FY2024, which is 709.56% up from last year.
  • Latest data reveals that Altimmune reported Operating Expenses of $20.9 million as of Q3 2025, which was down 1577.59% from $22.9 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Operating Expenses ranged from a high of $33.7 million in Q4 2023 and a low of $15.7 million during Q1 2021
  • In the last 5 years, Altimmune's Operating Expenses had a median value of $23.0 million in 2022 and averaged $23.9 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 10870.43% in 2021, then crashed by 2611.11% in 2024.
  • Over the past 5 years, Altimmune's Operating Expenses (Quarter) stood at $27.3 million in 2021, then fell by 15.69% to $23.0 million in 2022, then soared by 46.45% to $33.7 million in 2023, then fell by 26.11% to $24.9 million in 2024, then decreased by 16.11% to $20.9 million in 2025.
  • Its last three reported values are $20.9 million in Q3 2025, $22.9 million for Q2 2025, and $21.8 million during Q1 2025.